Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: A new era of hormonal therapies is born

Therapeutic Advances in Urology

Volumn 4, Issue 4, 2012, Pages 167-178

  Schweizer, Michael T ^a   Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

abiraterone; androgen; androgen receptor; enzalutamide; galeterone; orteronel; prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ARN 509; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICALUTAMIDE; CYTOCHROME P450 17; DEXAMETHASONE; DIURETIC AGENT; DOCETAXEL; EPLERENONE; GALETERONE; KETOCONAZOLE; ORTERONEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADVANCED CANCER; ANDROGEN SYNTHESIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; FATIGUE; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; HYPOKALEMIA; LEG EDEMA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84863933929     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287212452196     Document Type: Article

References (54)

1. Agus D. Stadler W. Shevrin L. Hart G. MacVicar O. Hamid J. (2011) Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in meta-static castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study. J Clin Oncol 29(Suppl.): abstract 4531.
2. Antonarakis E. Eisenberger M. (2011) Expanding treatment options for metastatic prostate cancer. N Engl J Med 364: 2055–2058.
3. Attard G. Reid A. Auchus R. Hughes B. Cassidy A. Thompson E. (2012) Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 97: 507–516.
4. Attard G. Reid A. Olmos D. De Bono J. (2009a) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69: 4937–4940.
5. Attard G. Reid A. Yap T. Raynaud F. Dowsett M. Settatree S. (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26: 4563–4571.
6. Attard G. Swennenhuis J. Olmos D. Reid A. Vickers E. A–Hern R. (2009b) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69: 2912–2918.
7. Berthold D. Pond G. Soban F. De Wit R. Eisenberger M. Tannock I. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242–245.
8. Bryce A. Ryan C. (2012) Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin Pharmacol Ther 91: 101–108.
9. Buchanan G. Irvine R. Coetzee G. Tilley W. (2001) Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20: 207–223.
10. Cai C. Chen S. Ng P. Bubley G. Nelson P. Mostaghel E. (2011) Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 71: 6503–6513.
11. Cai H. Babic I. Wei X. Huang J. Witte O.N. (2011) Invasive prostate carcinoma driven by C-Src and androgen receptor synergy. Cancer Res 71: 862–872.
12. Carver B. Chapinski C. Wongvipat J. Hieronymus H. Chen Y. Chandarlapaty S. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19: 575–586.
13. Clegg N.J. Wongvipat J. Joseph J.D. Tran C. Ouk S. Dilhas A. (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72: 1494–1503.
14. Danila D. Anand A. Sung C. Heller G. Leversha M. Cao L. (2011) TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 60: 897–904.
15. Danila D. Morris M. De Bono J. Ryan C. Denmeade S. Smith M. (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28: 1496–1501.
16. Darshan M. Loftus M. Thadani-Mulero M. Levy B. Escuin D. Zhou X. (2011) Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71: 6019–6029.
17. De Bono J. Logothetis C. Molina A. Fizazi K. North S. Chu L. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995–2005.
18. De Bono J. Oudard S. Ozguroglu M. Hansen S. Machiels J. Kocak I. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147–1154.
19. De Bono J. Scher H. Montgomery R. Parker C. Miller M. Tissing H. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302–6309.
20. Feldman B. Feldman D. (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34–45.
21. Foster W. Car B. Shi H. Levesque P. Obermeier M. Gan J. (2011) Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 71: 480–488.
22. Handratta V. Vasaitis T. Njar V. Gediya L. Kataria R. Chopra P. (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 48: 2972–2984.
23. Hellerstedt B. Pienta K. (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52: 154–179.
24. Holzbeierlein J. Lal P. Latulippe E. Smith A. Satagopan J. Zhang L. (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164: 217–227.
25. Hu R. Dunn T. Wei S. Isharwal S. Veltri R. Humphreys E. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16–22.
26. Huggins C. Hodges C. (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297.
27. Janssen Research & Development, LLC (2012) Study unblinded: ZYTIGA® (abiraterone acetate) plus prednisone for asymptomatic or mildly symptomatic chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Press release issued 8 March 2012. Available from: http://www.jnj.com/connect/news/all/study-unblinded-zytiga-abiraterone-acetate-plus-prednisone-for-asymptomatic-or-mildly-symptomatic-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate-cancer [ accessed 21 April 2012].
28. Jarman M. Barrie S. Llera J. (1998) The 16,17-double bond is needed for irreversible inhibition of human cytochrome P45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem 41: 5375–5381.
29. Kantoff P. Higano C. Shore N. Berger E. Small E. Penson D. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411–422.
30. Knudsen K. Scher H. (2009) Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15: 4792–4798.
31. Kohli M. Tindall D. (2010) New Developments in the medical management of prostate cancer. Mayo Clin Proc 85: 77–86.
32. Mohler J. (2008) Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 617: 223–234.
33. Montgomery R. Mostaghel E. Vessella R. Hess D. Kalhorn T. Higano C. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447–4454.
34. Morote J. Planas J. Salvador C. Raventos C. Catalan R. Reventos J. (2009) Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 103: 332–335; discussion 335.
35. Mostaghel E. Marck B. Plymate S. Vessella R. Balk S. Matsumoto A. (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17: 5913–5925.
36. Nacusi L. Tindall D. (2009) Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab 4: 417–422.
37. Rathkopf D. Danila D. Morris M. Slovin S. Steinbrecher J. Arauz G.(2012) Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): phase I results of a Prostate Cancer Clinical Trials Consortium study. J Clin Oncol 30(Suppl. 5): abstract 43.
38. Ryan C. Li J. Kheoh T. Scher H. Molina A. (2012) Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): results of the COU-AA-301 phase 3 randomized trial. American Association for Cancer Research Annual Meeting 2012, 31 March–4 April 2012, Chicago, IL. Abstract LB-434.
39. Ryan C. Smith M. Fong L. Rosenberg J. Kantoff P. Raynaud F. (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28: 1481–1488.
40. Ryan C. Tindall D. (2011) Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29: 3651–3658.
41. Scher H. Beer T. Higano C. Anand A. Taplin M. Efstathiou E. (2010) Antitumour activity of Mdv3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375: 1437–1446.
42. Scher H. Fizazi K. Saad F. Taplin M. Sternberg C. Miller K. (2012a) Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer post docetaxel: results from the phase III AFFIRM study. J Clin Oncol 30(Suppl. 5): abstract LBA1.
43. Scher H. Fizazi K. Saad F. Taplin M. Sternberg C. Miller K. (2012b) Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer post docetaxel: results from the phase III AFFIRM study. 2012 ASCO Genitourinary Cancers Symposium, 2–4 February 2012, San Francisco, CA. Abstract LBA1
44. Scher H. Heller G. Molina A. Kheoh T. Attard G. Moreira J. (2011) Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 29(Suppl.): abstract LBA4517.
45. Small E. Halabi S. Dawson N. Stadler W. Rini B. Picus J. (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22: 1025–1033.
46. Stanbrough M. Bubley G. Ross K. Golub T. Rubin M. Penning T. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815–2825.
47. Stein M. Goodin S. Dipaola R. (2012) Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res 18: 1848–1854.
48. Taplin M. Chu F. Morrison J. Pili R. Rettig M. Stephenson J. (2012) ARMOR1: safety of galeterone (TOK-001) in a phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC). American Association for Cancer Research Annual Meeting 2012, 31 March–4 April 2012, Chicago, IL. Abstract CT-07
49. Tomlins S. Rhodes D. Perner S. Dhanasekaran S. Mehra R. Sun X. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648.
50. Tran C. Ouk S. Clegg N. Chen Y. Watson P. Arora V. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787–790.
51. Vasaitis T. Belosay A. Schayowitz A. Khandelwal A. Chopra P. Gediya L. (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1h-benzimidazole-1-Yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7: 2348–2357.
52. Vasaitis T. Bruno R. Njar V. (2011) CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 125: 23–31.
53. Xin L. Teitell M. Lawson D. Kwon A. Mellinghoff I. Witte O. (2006) Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A 103: 7789–7794.
54. Zhu M. Horbinski C. Garzotto M. Qian D. Beer T. Kyprianou N. (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70: 7992–8002.